Michael Martino
Chief Executive Officer bei AMPIO PHARMACEUTICALS, INC.
Vermögen: 3 537 $ am 31.03.2024
Profil
Michael A.
Martino was the founder of Arzeda Corp., a company founded in 2008, where he held the title of President & Chief Executive Officer from 2008 to 2011.
He is currently the CEO, Chief Financial Officer, Secretary & Director at Ampio Pharmaceuticals, Inc., the Chief Executive Officer & Director at HemaFlo Therapeutics, Inc., a Director at Ambit Biosciences Corp., and a Director at CaraVan Biologix.
Mr. Martino's former positions include being the President & Chief Executive Officer of Sonus Pharmaceuticals, Inc. from 1998 to 2008, the President, Chief Executive Officer & Director of Ambit Biosciences Corp.
from 2011 to 2014, and the SVP-Innovation, Business Development & Strategy at CareFusion Corp.
He also served as a Director at OncoGenex Pharmaceuticals, Inc., Excision BioTherapeutics, Inc., and the Technology Alliance.
Additionally, Mr. Martino was the Chairman of the Washington Biotechnology & Biomedical Association and held the position of VP-Strategic Planning & Corporate Development at Mallinckrodt Medical, Inc. from 1983 to 1998.
He served as a Trustee at Roanoke College from 2016 to 2020.
Mr. Martino obtained an undergraduate degree from Roanoke College and an MBA from Virginia Polytechnic Institute & State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.03.2024 | 3 845 ( 0,46% ) | 3 537 $ | 31.03.2024 |
Aktive Positionen von Michael Martino
| Unternehmen | Position | Beginn |
|---|---|---|
| AMBIT BIOSCIENCES CORP | Director/Board Member | 13.10.2021 |
| AMPIO PHARMACEUTICALS, INC. | Chief Executive Officer | 22.11.2021 |
HemaFlo Therapeutics, Inc.
 HemaFlo Therapeutics, Inc. BiotechnologyHealth Technology HemaFlo Therapeutics, Inc. is an American private company that develops drag-reducing polymers (DRP) to improve blood flow in acute and chronic conditions associated with decreased tissue perfusion. DRPs are administered intravenously and work mechanically to reduce friction in flowing blood and stimulate blood vessel dilation, resulting in improved blood flow without increasing blood pressure. The CEO of the company is Michael A. Martino. | Chief Executive Officer | - |
| CaraVan Biologix | Director/Board Member | - |
Ehemalige bekannte Positionen von Michael Martino
| Unternehmen | Position | Ende |
|---|---|---|
| Roanoke College | Director/Board Member | 01.01.2020 |
OncoGenex Pharmaceuticals, Inc.
 OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Director/Board Member | 08.06.2010 |
Sonus Pharmaceuticals, Inc.
 Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA. | President | 22.08.2008 |
Mallinckrodt Medical, Inc.
 Mallinckrodt Medical, Inc. Medical SpecialtiesHealth Technology Mallinckrodt Medical, Inc. manufactures and markets healthcare products. Its products include contrast media & delivery systems, radiology imaging products, radiopharmaceuticals and urology imaging systems. The company is headquartered in Pointe-Claire, Canada. | Corporate Officer/Principal | 01.01.1998 |
Excision BioTherapeutics, Inc.
 Excision BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA. | Director/Board Member | - |
Ausbildung von Michael Martino
| Roanoke College | Undergraduate Degree |
| Virginia Polytechnic Institute & State University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AMPIO PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 11 |
|---|---|
Sonus Pharmaceuticals, Inc.
Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA. | Health Technology |
Ambit Biosciences Corp.
 Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
CareFusion Corp.
 CareFusion Corp. Medical DistributorsDistribution Services CareFusion Corp. engages in the manufactures of medical equipment and device. The company was founded on February 4, 2009 and is headquartered in San Diego, CA. | Distribution Services |
Mallinckrodt Medical, Inc.
Mallinckrodt Medical, Inc. Medical SpecialtiesHealth Technology Mallinckrodt Medical, Inc. manufactures and markets healthcare products. Its products include contrast media & delivery systems, radiology imaging products, radiopharmaceuticals and urology imaging systems. The company is headquartered in Pointe-Claire, Canada. | Health Technology |
Technology Alliance
 Technology Alliance Miscellaneous Commercial ServicesCommercial Services Technology Alliance supports and promotes technology-based businesses and research institutions. It organizes programs, events, data analysis, and policy activities for education, research, and entrepreneurship technology advancement. The company was founded by William H. Gates Sr. in 1996 and is headquartered in Seattle, WA. | Commercial Services |
| Washington Biotechnology & Biomedical Association | |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Health Technology |
Arzeda Corp.
 Arzeda Corp. BiotechnologyHealth Technology Arzeda Corp. operates as a synthetic biology company. It works thru agriculture, functionalized sweeteners and ingredients, chemicals and materials, and pharmaceuticals and diagnostics. The company was founded by Eric Althoff, David Baker, Daniela Grabs-R?thlisberger, Michael A. Martino and Alexandre Zanghellini in 2008 and is headquartered in Seattle, WA. | Health Technology |
Excision BioTherapeutics, Inc.
Excision BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA. | Commercial Services |
HemaFlo Therapeutics, Inc.
HemaFlo Therapeutics, Inc. BiotechnologyHealth Technology HemaFlo Therapeutics, Inc. is an American private company that develops drag-reducing polymers (DRP) to improve blood flow in acute and chronic conditions associated with decreased tissue perfusion. DRPs are administered intravenously and work mechanically to reduce friction in flowing blood and stimulate blood vessel dilation, resulting in improved blood flow without increasing blood pressure. The CEO of the company is Michael A. Martino. | Health Technology |
| CaraVan Biologix |
